ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

ClinicalTrials.gov ID: NCT02752074

Public ClinicalTrials.gov record NCT02752074. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Study identification

NCT ID
NCT02752074
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Incyte Corporation
Industry
Enrollment
706 participants

Conditions and interventions

Conditions

Interventions

  • pembrolizumab + epacadostat Drug
  • pembrolizumab + placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 20, 2016
Primary completion
Jan 7, 2018
Completion
Aug 15, 2019
Last update posted
Aug 23, 2025

2016 – 2019

United States locations

U.S. sites
34
U.S. states
25
U.S. cities
34
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Scottsdale Arizona
Not listed Little Rock Arkansas
Not listed Los Angeles California
Not listed San Francisco California
Not listed Santa Barbara California
Not listed Santa Monica California
Not listed Aurora Colorado
Not listed Denver Colorado
Not listed Washington D.C. District of Columbia
Not listed Fort Lauderdale Florida
Not listed Jacksonville Florida
Not listed Ocala Florida
Not listed West Palm Beach Florida
Not listed Chicago Illinois
Not listed Peoria Illinois
Not listed Iowa City Iowa
Not listed Kansas City Kansas
Not listed Lutherville Maryland
Not listed Boston Massachusetts
Not listed Ann Arbor Michigan
Not listed Fridley Minnesota
Not listed Billings Montana
Not listed Omaha Nebraska
Not listed Las Vegas Nevada
Not listed Rochester New York
Not listed Charlotte North Carolina
Not listed Philadelphia Pennsylvania
Not listed Nashville Tennessee
Not listed Austin Texas
Not listed Dallas Texas
Not listed Salt Lake City Utah
Not listed Fairfax Virginia
Not listed Spokane Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02752074, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 23, 2025 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02752074 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →